
Quarterly ResultNov 2, 2026, 04:12 PM
Cerus Corp Q3 Revenue $64.0M (+6% YoY); Positive RedeS Study Results
AI Summary
Cerus Corporation announced its third quarter 2026 financial results, reporting a 10% year-over-year increase in product revenue to $57.7 million and total revenue of $64.0 million. The company also highlighted positive topline results from its Phase 3 RedeS study for the INTERCEPT Blood System for red blood cells. Cerus achieved positive Non-GAAP Adjusted EBITDA of $5.7 million and generated $3.0 million in operating cash flow. The company reiterated its full-year 2026 product revenue guidance and announced the appointment of Betsy Jensen as chief human resources officer.
Key Highlights
- Cerus Corporation reported Q3 2026 product revenue of $57.7 million, a 10% increase year-over-year.
- Total revenue for Q3 2026 reached $64.0 million, up 6% year-over-year.
- Announced positive topline Phase 3 RedeS results for the INTERCEPT Blood System for red blood cells.
- Achieved positive Non-GAAP Adjusted EBITDA of $5.7 million in Q3 2026, compared to $5.0 million in Q3 2025.
- Generated operating cash flow of $3.0 million in Q3 2026.
- Appointed Betsy Jensen as chief human resources officer, effective December 2026.
- Reiterated full-year 2026 product revenue guidance of $229 million to $231 million.
Price Impact
More from CERS